Novartis: Cosentyx continues to show benefits.
(CercleFinance.com) - Novartis' Cosentyx shows, at 3 years, sustained improvements in the signs and symptoms for active ankylosing spondylitis, a life-long debilitating inflammatory disease, the drugmaker said on Thursday.
In a phase III study, 80% of patients consistently achieved a positive response, a number which is consistent with previous findings where Cosentyx demonstrated sustained improvements in approximately 80% of active psoriatic arthritis (PsA) patients.
Additional data show rapid and sustained pain relief with Cosentyx in PsA as early as week 3.
Novartis is now recruiting patients for a new head-to-head clinical trial intended to show superiority of Cosentyx versus AbbVie's Humira in PsA.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
In a phase III study, 80% of patients consistently achieved a positive response, a number which is consistent with previous findings where Cosentyx demonstrated sustained improvements in approximately 80% of active psoriatic arthritis (PsA) patients.
Additional data show rapid and sustained pain relief with Cosentyx in PsA as early as week 3.
Novartis is now recruiting patients for a new head-to-head clinical trial intended to show superiority of Cosentyx versus AbbVie's Humira in PsA.
Copyright (c) 2017 CercleFinance.com. All rights reserved.